Stock Fundamentals

Company Information

Company Name
Entera Bio Ltd
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: IL0011429839
CIK: 0001638097
CUSIP: M40527109
Currency: USD
Full Time Employees: 20
Phone: 972 2 532 7151
Fiscal Year End: December
IPO Date: Jun 28, 2018
Description:

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

Address:

Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002

Directors & Officers

Name Title Year Born
Ms. Miranda J. Toledano M.B.A. CEO & Director 1977
Dr. Hillel Galitzer M.B.A., Ph.D. Chief Operating Officer 1978
Dr. Gregory Burshtein Ph.D. Chief of Research & Development 1977
Ms. Dana Yaacov-Garbeli CPA Chief Financial Officer 1983
Dr. Rachel B. Wagman Chief Clinical Advisor NA
Ms. Cherin Smith Executive VP & Head of Clinical Operations NA
Dr. Constantin Itin Ph.D., R.Ph. Head of Biopharmaceutics & Bioanalytics NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 09, 2026 Geno J Germano N/A Purchase 20.00K $1.30 $26.00K
Mar 05, 2026 Sean Ellis N/A Purchase 10.00K $1.23 $12.30K
Feb 09, 2026 Sean Ellis N/A Purchase 18.00K $1.24 $22.32K
Feb 09, 2026 Steven D Rubin N/A Purchase 10.00K $1.20 $12.00K
Dec 29, 2025 Miranda Jayne Toledano N/A Purchase 11.00K $1.81 $19.91K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Knoll Capital Management LP 5.88M Mar 31, 2026 11.95% $3.59 0.00%
Renaissance Technologies Corp 473.44K Mar 31, 2026 0.96% $0.00 338.37%
Parkman Healthcare Partners LLC 288.67K Mar 31, 2026 0.59% $0.03 4.94%
Citadel Advisors Llc 245.58K Mar 31, 2026 0.50% $0.00 510.43%
Seven Fleet Capital Management LP 205.54K Mar 31, 2026 0.42% $0.07 51.90%
Marshall Wace Asset Management Ltd 195.78K Mar 31, 2026 0.40% $0.00 -68.79%
Northern Trust Corp 146.85K Mar 31, 2026 0.30% $0.00 -1.22%
XTX Topco Ltd 131.62K Mar 31, 2026 0.27% $0.00 0.00%
Schonfeld Strategic Advisors LLC 55.22K Mar 31, 2026 0.11% $0.00 -90.74%
Signature Estate & Investment Advisors 47.33K Mar 31, 2026 0.10% $0.00 0.00%
HighTower Advisors, LLC 36.83K Mar 31, 2026 0.07% $0.00 -14.63%
Jane Street Group LLC 32.92K Mar 31, 2026 0.07% $0.00 -55.56%
Diadema Partners LP 23.26K Mar 31, 2026 0.05% $0.00 0.00%
Geode Capital Management, LLC 21.14K Mar 31, 2026 0.04% $0.00 0.00%
Gem Investment Advisors, LLC 19.14K Mar 31, 2026 0.04% $0.02 0.00%
HRT FINANCIAL LLC 15.49K Mar 31, 2026 0.03% $0.00 0.00%
Point72 Asset Management, L.P. 12.38K Mar 31, 2026 0.03% $0.00 -98.96%
Bank of America Corp 12.00K Mar 31, 2026 0.02% $0.00 -20.00%
PNC Financial Services Group Inc 10.00K Mar 31, 2026 0.02% $0.00 0.00%
JPMorgan Chase & Co 7.15K Mar 31, 2026 0.01% $0.00 0.00%

Shares Statistics

Shares Outstanding: 49.29M
Shares Float: 40.37M
% Insiders: 2,310.00%
% Institutions: 1,598.00%
Short % Float: 0.78%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Nasdaq Composite Index 29.91K 0.06% ▲ 41.50% Apr 30, 2026

Valuation Metrics

Enterprise Value: $77.89M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $81.58M
EBITDA: $-12.48M
Book Value: $0.23
Earnings/Share: $-0.26
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -45.01%
ROE (TTM): -82.33%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -100.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 3.23x 0.02x 0.18x N/A -0.02x
2024-12-31 7.63x 0.02x 0.14x N/A -0.02x
2023-12-31 10.32x 0.01x 0.12x N/A -0.02x
2022-12-31 9.58x 0.01x 0.10x -0.50x -0.01x
2021-12-31 8.01x 0.01x 0.13x -421.28x -0.01x
2020-12-31 4.95x 0.03x 0.23x -7.98x -0.02x
2019-12-31 3.41x 0.01x 0.29x -136.36x -0.02x
2018-12-31 6.97x 0.00x 0.24x N/A 0.00x
2017-12-31 6.15x -1.31x 3.38x N/A -3.73x
2016-12-31 0.52x -0.58x 5.02x N/A -2.76x
2015-12-31 2.36x -1.64x 10.35x N/A -11.50x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ENTX.US!